You are here: HomeSolutionsIndustriesConsumer Health
print my pages

Country Report

Consumer Health in Belgium

Apr 2011

Price: $2,400

About this Report

About this Report

Delivery method: instant download
Report format: PDF doc_pdf.png (download a sample)
Market statistics: Excel workbook doc_excel_table.png (download a sample)

Overview

Discover the latest market trends and uncover sources of future market growth for the Consumer Health industry in Belgium with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Consumer Health industry in Belgium, our research will save you time and money while empowering you to make informed, profitable decisions.

When you purchase this report, you also get the data and the content from these category reports in Belgium for free:

The Consumer Health in Belgium market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth  
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Consumer Health in Belgium?
  • What are the major brands in Belgium?
  • What are the main trends in OTC Healthcare?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Sample Analysis

EXECUTIVE SUMMARY

Surprising slowdown in 2010

While consumer healthcare still posted robust current value growth in 2009, the year of recession, sales suddenly declined during the first half of 2010 and then recovered slightly. This resulted in under-average growth in overall sales of consumer healthcare in 2010 compared with the appreciable CAGR of the review period. Mainstream categories, including analgesics, cough, cold and allergy remedies and vitamins, roughly levelled out in 2010, while the other categories were not sufficiently dynamic to offset their stagnation.

Near absence of infectious disease outbreaks and wait-and-see attitude

Key factors in this slowdown were numerous, and included the near absence of infectious diseases. According to industry sources, the number of cough, cold, flu and gastroenteritis outbreaks was so limited that the level of epidemiology was not reached in the winter of 2010 – the first time in many years. Then, the fear of H1N1 disappeared in early 2010, but overstocks of analgesics and cough, cold and allergy remedies remained in pharmacies and consumers’ homes. This contributed to a kind of wait-and-see attitude that was particularly manifest in digestive remedies. In this category traditional antacid manufacturers seemed to wait for the impact of the creation of OTC PPIs (proton pump inhibitors) in Belgium in the short term. Lastly, the negative results of some medical surveys hampered the potential of joint care products – one of the most dynamic segments in the vitamins and dietary supplements environment.

Market still fragmented despite growing global consolidation

The competitive environment was still characterised by a high level of fragmentation in 2010, with no clear leader. Despite some improvements in recent years, legislation regarding registration, pricing, distribution and advertising in Belgium was still rather less favourable to manufacturers than in the majority of Western European countries. Coupled with the aforementioned negative climate, this resulted in a relatively low level of marketing activity and the stagnation of the top 10 players in 2010. This contrasted with 2009, which saw on-going mergers and acquisitions among pharmaceutical companies on a worldwide scale, resulting in a consolidation of shares in Belgium.

No real change in distribution that remains under the control of pharmacies

As in France, chemists/pharmacies still monopolised sales of standard analgesics, digestive remedies, NRT smoking cessation aids and eye care products despite rumours of deregulation during the second half of the review period. This channel also held an overwhelmingly dominant share in all other categories. This dominance left little room for other distribution channels, the most important being grocery retailers. From a low base, parapharmacies/drugstores have gained ground in recent years by virtue of the dynamism of the Dutch chain Kruidvat. In the modest non-store retailing channel, Internet retailing was the main growth driver, mainly since the launch of on-line pharmacies such as newpharma.be.

Modest growth anticipated in short term

The weak economic recovery should not significantly improve consumer spending in the consumer health and wellness market, meaning that growth rates will be much lower than those seen over the review period. Consumers could be forced to shift consumption away from remedies and particularly supplements with added value, towards more basic alternatives. The less regulated niches which previously drove OTC sales are those that can be considered discretionary, and are thus most likely to be weakened by the sluggish economic context. The more mature and better established products, which are generally more necessary than preventative treatments, are likely to perform better in actual value terms, but can still be jeopardised by other years which do not see widespread outbreaks of infectious diseases.

Table of Contents

Table of Contents

Consumer Health in Belgium - Industry Overview

EXECUTIVE SUMMARY

Surprising slowdown in 2010

Near absence of infectious disease outbreaks and wait-and-see attitude

Market still fragmented despite growing global consolidation

No real change in distribution that remains under the control of pharmacies

Modest growth anticipated in short term

KEY TRENDS AND DEVELOPMENTS

Weather and disease have greater impact than economy

Remedies for increasingly hectic lifestyles

Changes in authorisations and medical surveys see mixed results

Two-sided impact of the health and wellness trend

No real questioning of distribution model in Belgium

Slightly more favourable ground for local players

MARKET INDICATORS

  • Table 1 Consumer Expenditure on Health Goods and Medical Services 2005-2010
  • Table 2 Life Expectancy at Birth 2005-2010

MARKET DATA

  • Table 3 Sales of Consumer Health by Category: Value 2005-2010
  • Table 4 Sales of Consumer Health by Category: % Value Growth 2005-2010
  • Table 5 Consumer Health Company Shares by Value 2006-2010
  • Table 6 Consumer Health Brand Shares by Value 2007-2010
  • Table 7 Penetration of Private Label by Category 2005-2010
  • Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2005-2010
  • Table 9 Sales of Consumer Health by Category and Distribution Format: % Analysis 2010
  • Table 10 Forecast Sales of Consumer Health by Category: Value 2010-2015
  • Table 11 Forecast Sales of Consumer Health by Category: % Value Growth 2010-2015

APPENDIX

OTC Registration and Classification

Vitamins and Dietary Supplements – Registration and Classification

Switch Climate

Self-medication and Preventative Medicine

Generics

Switches

  • Summary 1 OTC Healthcare Switches 2008-2010

DEFINITIONS

  • Summary 2 Research Sources

Consumer Health in Belgium - Company Profiles

Biodiphar NV SA in Consumer Health (Belgium)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND AND PRODUCTION

COMPETITIVE POSITIONING

  • Summary 5 Biodiphar NV SA: Competitive Position 2010

Laboratoires Pharmaceutiques Trenker SA in Consumer Health (Belgium)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND AND PRODUCTION

COMPETITIVE POSITIONING

  • Summary 8 Laboratoires Pharmaceutiques Trenker: Competitive Position 2010

Omega Pharma NV in Consumer Health (Belgium)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 11 Omega Pharma NV: Production Statistics 2005

COMPETITIVE POSITIONING

  • Summary 12 Omega Pharma NV: Competitive Position 2010

Patch Pharma SA in Consumer Health (Belgium)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND AND PRODUCTION

COMPETITIVE POSITIONING

Tilman NV SA in Consumer Health (Belgium)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 17 Tilman NV SA: Competitive Position 2010

Adult Mouth Care in Belgium - Category Analysis

HEADLINES

TRENDS

  • The main event over the last couple of years was growing competition from mass mouthwash brands, which are not included in consumer healthcare. In the middle of the review period players such as Pfizer Consumer Healthcare and Colgate-Palmolive saw unexploited potential in this area, and reactivated their brands from 2008. In 2010 Listerine continued to record double-digit current value growth.

SWITCHES

COMPETITIVE LANDSCAPE

  • With almost half of category value sales, Pfizer Consumer Healthcare still drove sales in adult mouth care in 2010. The popularity of its flagship Hextril brand resulted in a rather high level of self-medication. However, this brand slowed down in 2009 and suddenly dropped in the second half of 2010, notably due to the focus of its Pfizer Consumer Healthcare on Listerine, the leading brand in mass mouth wash.

PROSPECTS

  • The outlook is rather grey for mouth care. According to players operating in toiletries, the level of concern regarding oral hygiene in Belgium is among the lowest in Europe. Around two-thirds of Belgian consumers buy less than one toothbrush per year, which is much lower than the three toothbrushes purchased by Swiss consumers. Thus, limited consumer awareness regarding the incidence of mouth ulcers and other oral hygiene problems is not likely to improve in the short term.

CATEGORY DATA

  • Table 12 Sales of Adult Mouth Care: Value 2005-2010
  • Table 13 Sales of Adult Mouth Care: % Value Growth 2005-2010
  • Table 14 Adult Mouth Care Company Shares by Value 2006-2010
  • Table 15 Adult Mouth Care Brand Shares by Value 2007-2010
  • Table 16 Forecast Sales of Adult Mouth Care: Value 2010-2015
  • Table 17 Forecast Sales of Adult Mouth Care: % Value Growth 2010-2015

Analgesics in Belgium - Category Analysis

HEADLINES

TRENDS

  • By contrast with a still favourable performance in 2009, 2010 witnessed an exceptional accumulation of negative factors. First, despite a late awakening in December there were a very limited number of serious infectious disease outbreaks. Even colds were rare until November. Then, the end of the fear regarding the H1N1 flu virus resulted in a backlash: given that both pharmacists and consumers overstocked, sales slumped in the winter of 2010.

SWITCHES

COMPETITIVE LANDSCAPE

  • In a concentrated competitive environment, UPSA Médica (Bristol-Myers Squibb) remained the clear leader in analgesics. 2010 was not a good year for UPSA Médica, however, as with 37% of category value its flagship Dafalgan brand was obviously the most affected by the negative context. Even so, the Dafalgan brand still slightly progressed by combining press and in-store campaigns and a semi-ethical approach in terms of advertising. It continued to organise the cannibalisation of its standard 500mg variant with Dafalgan Forte AG (1,000mg). UPSA Médica also benefited from the remodelling of its sales force since 2008, amalgamating its OTC and Rx teams to work with both doctors and chemists/pharmacists. Dafalgan has also benefited from the support of the European Back Association and EULAR (European League against Rheumatism) since 2008.

PROSPECTS

  • According to some experts, even the leader Dafalgan demonstrated signs of slowdown, in contrast with previous years of insolent progression. However, after leaving the field clear to Nurofen in the area of new formats over 2009-2010, Dafalgan by Nurofen should counter-attack with new variants in 2011-2012. This should represent an opportunity for the category and will probably help its recovery. In addition, overall sales could be fuelled by the deregulation of retailing of OTC analgesics in the area of distribution, for example with Internet sales. Manufacturers of analgesics could benefit from the progress of self-medication among Belgians. Consumers are increasingly seeking information regarding minor ailments on websites. Thus, they can avoid visiting a doctor in some cases by buying OTC analgesics without a doctor’s recommendations.

CATEGORY DATA

  • Table 18 Sales of Analgesics by Category: Value 2005-2010
  • Table 19 Sales of Analgesics by Category: % Value Growth 2005-2010
  • Table 20 Topical Analgesics/Anaesthetic by Format: % Value Breakdown 2005-2010
  • Table 21 Analgesics Company Shares by Value 2006-2010
  • Table 22 Analgesics Brand Shares by Value 2007-2010
  • Table 23 Forecast Sales of Analgesics by Category: Value 2010-2015
  • Table 24 Forecast Sales of Analgesics by Category: % Value Growth 2010-2015

Calming and Sleeping in Belgium - Category Analysis

HEADLINES

TRENDS

  • Sales of calming and sleeping products seemed to see growing fortune on the back of the development of stress and insomnia given the increasingly hectic lifestyles of Belgian consumers. Such products are the first step alternatives to Rx sedatives, while many Belgians still distrust Rx products and are wary of the danger of addiction.

SWITCHES

COMPETITIVE LANDSCAPE

  • The leading brand was Melisana Sedinal by Klosterfrau with a 13% value share in 2010 – and a much higher share only in pharmacies. Nonetheless, Klosterfrau has not supported this brand particularly strongly, and Melisana Sedinal has had to face strong competition from some other brands, as well as the emergence of other distribution channels.

PROSPECTS

  • The new European legislation of 2010 regarding herbal products could dampen category sales over the forecast period. In addition, the expansion of sales through drugstores and supermarkets is likely to exacerbate competition, resulting in price erosion. This has previously occurred in other deregulated areas, such as dietary supplements.

CATEGORY DATA

  • Table 25 Sales of Calming and Sleeping: Value 2005-2010
  • Table 26 Sales of Calming and Sleeping: % Value Growth 2005-2010
  • Table 27 Calming and Sleeping Company Shares by Value 2006-2010
  • Table 28 Calming and Sleeping Brand Shares by Value 2007-2010
  • Table 29 Forecast Sales of Calming and Sleeping: Value 2010-2015
  • Table 30 Forecast Sales of Calming and Sleeping: % Value Growth 2010-2015

Cough, Cold and Allergy (Hay Fever) Remedies in Belgium - Category Analysis

HEADLINES

TRENDS

  • The cough, cold and allergy (hay fever) remedies environment was subject to the same fate as analgesics. 2008 and 2009 were so exceptional in terms of infectious diseases that the relative lack of ailments such as coughs and allergies at the end of 2009 and in the first half of 2010 dragged down the performance of the whole category. This contrasted with 2009, when manufacturers perceived that the fear of H1N1 (which has now disappeared) triggered more purchases of cough, cold and allergy products than usual.

SWITCHES

COMPETITIVE LANDSCAPE

  • Although it was fragmented in terms of brands, the competitive environment for cough, cold and allergy (hay fever) remedies was rather concentrated in terms of companies. The four top players, Procter & Gamble Eurocor NV SA, Solinest SA, Novartis Consumer Health SA NV and Sanofi-Synthélabo SA NV, accounted for a value share of 35% in 2010. Procter & Gamble Eurocor NV SA led in 2010 with a 14% value share by virtue of the high profile and strong sales of its Vicks umbrella brand, which is present in many categories.

PROSPECTS

  • Despite the interruption of 2010 due to ‘disastrous’ climatic context, the scope for development remains promising in cough, cold and allergy (hay fever) remedies. First, the recovery of combination products in cough, cold and allergy remedies under the impetus given by Otrivine Duo shows that this niche should not slump in the short term, in contrast with the first years of the review period. Then, like other mainstream categories, cough, cold and allergy (hay fever) remedies should benefit from a slow and progressive deregulation, notably in distribution. The great majority of products should still be sold by pharmacists in the short term, but marketers should nonetheless pay attention to the recent emergence of sales via the Internet – authorised since January 2009.

CATEGORY DATA

  • Table 31 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2005-2010
  • Table 32 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2005-2010
  • Table 33 Sales of Decongestants by Category: Value 2005-2010
  • Table 34 Sales of Decongestants by Category: % Value Growth 2005-2010
  • Table 35 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2005-2010
  • Table 36 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2005-2010
  • Table 37 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Value 2006-2010
  • Table 38 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Value 2007-2010
  • Table 39 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2010-2015
  • Table 40 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2010-2015

Digestive Remedies in Belgium - Category Analysis

HEADLINES

TRENDS

  • After the emergence of H2 blockers in OTC products, the main event in 2010 was in fact the absence of significant changes in digestive remedies. The category was at standstill due to the possible positive switch of “third-generation antacids”, with the expected entrance of PPIs (proton pump inhibitors) in the short term. In addition, digestive remedies are also victims of the absence of real economic recovery, as many consumers consider digestive remedies as “comfort products”.

SWITCHES

COMPETITIVE LANDSCAPE

  • Janssen-Cilag (owned by Johnson & Johnson) was the undisputed leader in a fragmented competitive environment in 2010. It captured 27% of the category value sales in 2010 due to its Motilium, Imodium and, to a lesser extent, Touristil brands in antacids, diarrhoeal remedies and motion sickness remedies. Its flagship Motilium brand largely monopolised the gastroprocinetic segment owing to its efficiency, its anti-nausea properties, and its convenience, thanks to the launch of an instant format in the middle of the review period. Still slightly dynamic, Imodium held the leading position in diarrhoeal remedies while Touristil, the leader of motion sickness remedies, waned in 2010.

PROSPECTS

  • In 2009, PPIs (proton pump inhibitors) emerged in the Belgian OTC market. However, at the time of writing PPIs were only available on an Rx basis, and Pantozol Control by Nycomed Christiaens SA or other PPIs with the same pantoprazole molecule should enter the Belgian market only in 2012 or 2013. In addition, marketers wonder if this emergence will represent a revolution for the category or a non-event. In 2010 the emergence of H2 blockers was disappointing, as this niche did not take off and remained a micro-niche at the end of the year.

CATEGORY DATA

  • Table 41 Sales of Digestive Remedies by Category: Value 2005-2010
  • Table 42 Sales of Digestive Remedies by Category: % Value Growth 2005-2010
  • Table 43 Digestive Remedies Company Shares by Value 2006-2010
  • Table 44 Digestive Remedies Brand Shares by Value 2007-2010
  • Table 45 Forecast Sales of Digestive Remedies by Category: Value 2010-2015
  • Table 46 Forecast Sales of Digestive Remedies by Category: % Value Growth 2010-2015

Ear Care in Belgium - Category Analysis

HEADLINES

TRENDS

  • In 2010 the predicted decline occurred due to ear care’s comfort status, and with consumers increasingly price sensitive sales waned in 2010. As a non-essential product, and due to renewed competition from cotton wool buds, ear care was also affected.

SWITCHES

COMPETITIVE LANDSCAPE

  • Laboratoires Chauvin SA led ear care with a 30% value share in 2010 thanks to its Cerulyx brand, historical leader of the category. Other players lagged far behind, and notably included Biologische Heilmittel Heel, Dolisos (a homeopathy specialist), Viatris and Sanofi-Synthélabo.

PROSPECTS

  • Several threats persist that should mitigate the potential of ear care in coming years. Other than the consequences of recession, the presence of a significant number of competitors may exhaust consumer interest during the forecast period, while some medical specialists will continue to question the side-effects of ear care. Manufacturers also cite indirect competition from cotton wool buds as dampening sales, as well as questions regarding the side-effects of some products.

CATEGORY DATA

  • Table 47 Sales of Ear Care: Value 2005-2010
  • Table 48 Sales of Ear Care: % Value Growth 2005-2010
  • Table 49 Ear Care Company Shares by Value 2006-2010
  • Table 50 Ear Care Brand Shares by Value 2007-2010
  • Table 51 Forecast Sales of Ear Care: Value 2010-2015
  • Table 52 Forecast Sales of Ear Care: % Value Growth 2010-2015

Emergency Contraception in Belgium - Category Analysis

HEADLINES

TRENDS

  • Over the last couple of years there were no other notable events than the introduction of EllaOne from Laboratoires HRA Pharma. This Rx emergency contraception product entered the Belgian market thanks to authorisation by the European Medicines Evaluation Agency (EMEA). This new brand had to shuffle the cards in the niche of emergency contraception thanks its efficacy until five days after sexual intercourse. Even so, it is an indirect competitor to the already existing NorLevo by Besins International Belgique SA, with GBO Laboratoires HRA Pharma, and Postinor from Mithra Pharmaceuticals.

COMPETITIVE LANDSCAPE

  • NorLevo by Laboratoires HRA Pharma was the absolute leading brand in emergency contraception with 75% of value sales in 2010. It is sold as a package with one blister of two tablets, each containing 0.75mg of levonorgestrel, a progestin. It does not contain oestrogens and its side-effects are deemed to be less aggressive. Two pills are necessary for one treatment.

PROSPECTS

  • There are still some threats which could dampen the potential of emergency contraception in coming years. The consumer base is likely to decline slightly due to new contraceptive methods, such as coils and implants, due to the ageing of the female population and lastly due to the competition from EllaOne. Priced at EUR29.90 in Belgium, this pill is too expensive for many consumers, but could be reimbursed soon for women over 21, which would fuel sales.

CATEGORY DATA

  • Table 53 Sales of Emergency Contraception: Value 2005-2010
  • Table 54 Sales of Emergency Contraception: % Value Growth 2005-2010
  • Table 55 Emergency Contraception Company Shares by Value 2006-2010
  • Table 56 Emergency Contraception Brand Shares by Value 2007-2010
  • Table 57 Forecast Sales of Emergency Contraception: Value 2010-2015
  • Table 58 Forecast Sales of Emergency Contraception: % Value Growth 2010-2015

Eye Care in Belgium - Category Analysis

HEADLINES

TRENDS

  • Correlated with climatic conditions in spring, allergy eye care always experienced irregular sales with frequent peaks and troughs. This was again the case over the last couple of years: after favourable weather in 2009, sales of allergy eye care were hindered by wet weather in May 2010 which limited the distribution of pollen. As a result allergy eye care declined by 3% in current value terms in 2010. This contrasted with the bulk of the review period, which benefited from rather favourable conditions – for instance atypically dry weather in spring 2009. Marketers observed a better fate in pure OTC allergy eye care than their Rx equivalents during this year. Even so, pure OTC products such as Allergodil performed better than Rx/OTC prescribed products in 2009 and 2010. This was notably attributed to the non-reimbursement of Rx and semi-ethical allergy eye care in Belgium.

SWITCHES

COMPETITIVE LANDSCAPE

  • Shifts in share were significant in eye care over the review period, with new innovations having the capacity to enable brand owners to quickly gain several percentage points of share in a short period at the expense of rivals. Following its introduction in the first half of the review period, Hyabak from Théa Pharma quickly captured brand leadership in 2007, and forged ahead over the last couple of years. Although it lost ground to Optive in 2008, it counter-attacked with an aggressive promotional campaign in 2009 and 2010 that enabled it to still post double-digit value growth in 2010.

PROSPECTS

  • Despite their efforts manufacturers have increasing doubts regarding the capacity of Belgian consumers to self-medicate in the area of eye care. Belgians accept directly buying vitamins, dietary supplements or cold, cough and allergy remedies when they are tired, stressed or have a cold. Nonetheless, only a minority can purchase for the first time a brand in eye care without the advice or the prescription from their ophthalmologist. Once the product has been prescribed once, they directly purchase it from pharmacists on an OTC basis. European deregulation enabled artificial tears to be sold through outlets other than chemists/pharmacies during the review period in Belgium. However, Belgians still depend on advice from chemists/pharmacists, and thus sales have not taken off in drugstores or supermarkets.

CATEGORY DATA

  • Table 59 Sales of Eye Care by Category: Value 2005-2010
  • Table 60 Sales of Eye Care by Category: % Value Growth 2005-2010
  • Table 61 Standard Eye Care by Type: % Value Breakdown 2007-2010
  • Table 62 Eye Care Company Shares by Value 2006-2010
  • Table 63 Eye Care Brand Shares by Value 2007-2010
  • Table 64 Forecast Sales of Eye Care by Category: Value 2010-2015
  • Table 65 Forecast Sales of Eye Care by Category: % Value Growth 2010-2015

Herbal/Traditional Products in Belgium - Category Analysis

HEADLINES

TRENDS

  • Negative factors tended to be increasingly numerous for sales of herbal/traditional products in 2009 and 2010. First, sales of herbal analgesics, and cough, cold and allergy (hay fever) remedies were curtailed by the near absence of infectious disease outbreaks during the bulk of 2010. Then, the imminent settlement of the European legislation regarding functional claims and dietary supplements hampered product launch activity in 2009 and 2010. The prospects of total questioning of herbal/traditional products in 2010 made this category much less attractive.

COMPETITIVE LANDSCAPE

  • In a highly fragmented competitive environment, Procter & Gamble and Solinest (distributor of Ricola in Belgium) were theoretically leading players. Nonetheless, herbal/traditional products specialists question this ranking, as this leadership stemmed from their medicated confectionery brands Vicks and Ricola. In fact, the real top players were medium-sized operators, by virtue of sufficient flexibility to recognise the most promising concepts and invest in them quickly. The rest of the competitive environment was made up of nearly 300 small laboratories offering at least one herbal brand and commanding marginal shares.

PROSPECTS

  • Industry sources have strong reservations regarding the outlook for herbal/traditional products. Some sources consider the growing fad for naturally-healthy and organic products in related markets should benefit the category. In addition, in some niches, a product launch or the success of one brand can still suddenly boost sales, such as herbal medicated skin care in recent years for example. Other sources are much less optimistic and think a growing number of consumers will cut purchases of non-essential products, notably herbal/traditional goods, which are rarely prescribed and/or reimbursed. In addition, the category should suffer from the competition posed by dietary supplements positioned as beneficial for intestinal and digestive health, such as probiotic supplements. Lastly, in herbal dietary supplements, a category driven by the image of youth and health, lifecycles will become logically shorter and shorter; all the more so as lobbying and scandals will continue to impact sales, as in vegetal oestrogens or St John’s wort during the review period.

CATEGORY DATA

  • Table 66 Sales of Herbal/Traditional Products: Value 2005-2010
  • Table 67 Sales of Herbal/Traditional Products: % Value Growth 2005-2010
  • Table 68 Herbal/Traditional Products Company Shares 2006-2010
  • Table 69 Herbal/Traditional Products Brand Shares 2007-2010
  • Table 70 Forecast Sales of Herbal/Traditional Products: Value 2010-2015
  • Table 71 Forecast Sales of Herbal/Traditional Products: % Value Growth 2010-2015

Medicated Skin Care in Belgium - Category Analysis

HEADLINES

TRENDS

  • Medicated skin care registered a downturn in demand in 2010. Sales seem to have been directly hit by the economic crisis and consumers subsequently watching their budgets more closely. As many products in medicated skin care are not considered crucial by consumers or face competition from reimbursed Rx products, this hampered self-medication in this category in 2010. In addition, the offensive the sensitivity/information campaigns regarding the danger of mycosis and other skin complaints, which began during the first half of the review period, was blunted in 2010.

SWITCHES

COMPETITIVE LANDSCAPE

  • The top five players accounted for 47% of total value sales in 2010. With a 13% value share in 2010, Janssen-Cilag (owned by Johnson & Johnson) was slightly ahead of Reckitt Benckiser SA NV and Leo Pharmaceutical Products Ltd. The Daktar umbrella brand in antifungals, and Nizoral, which leads medicated shampoos, enabled Janssen-Cilag to maintain its lead of medicated skin care in 2010.

PROSPECTS

  • Opinions differ regarding the projected fortunes of medicated skin care in coming years. On one hand some categories are sufficiently small that one key launch or the success of one brand could temporarily buoy overall medicated skin care sales. In addition, consumers want to take greater care of their body and, due to continuous information campaigns, an increasing number of potential consumers will become aware of issues related to skin. In addition, the category could benefit from the beginning of deregulation of its distribution with the launch of the first web shops selling OTC products, and notably medicated skin care.

CATEGORY DATA

  • Table 72 Sales of Medicated Skin Care by Category: Value 2005-2010
  • Table 73 Sales of Medicated Skin Care by Category: % Value Growth 2005-2010
  • Table 74 Acne Treatments by Format: % Value Breakdown 2005-2010
  • Table 75 Medicated Skin Care Company Shares by Value 2006-2010
  • Table 76 Medicated Skin Care Brand Shares by Value 2007-2010
  • Table 77 Acne Treatments Brand Shares by Value 2007-2010
  • Table 78 Hair Loss Treatments Brand Shares by Value 2007-2010
  • Table 79 Forecast Sales of Medicated Skin Care by Category: Value 2010-2015
  • Table 80 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2010-2015

NRT Smoking Cessation Aids in Belgium - Category Analysis

HEADLINES

TRENDS

  • Over the last couple of years anti-tobacco associations and manufacturers of NRT smoking cessation aids complained regarding the lack of significant measures against smoking. While sales of tobacco tended to decline over the decade, they recovered in recent years and notably increased by 8% in value in 2010 according to CRIOC (a consumer trade union). This was despite the partial ban on smoking in restaurants and public places, and price increases in 2010.

SWITCHES

COMPETITIVE LANDSCAPE

  • By acquiring the Nicorette brand in 2009, Janssen-Cilag NV became the clear leader of NRT smoking cessation aids. While consumers clearly shifted towards more convenient smoking cessation aids in recent years, Nicorette concentrated with success on modulable formats such as Nicorette Gum and Nicorette Microtab Lemon. Nicorette’s strategy paid off handsomely: it tried to recruit undecided and anxious smokers by helping them reduce their consumption – a first step to increase their self-confidence before stopping for good. As a result, Nicorette continued to enjoy robust growth in 2010.

PROSPECTS

  • The main event in the short term could be the ban on smoking in the last horeca establishments. This will mean a ban on smoking in all places of work and in all places accessible by the public. At the time of writing smoking is still permitted in casinos, pubs and nightclubs where only some pre-packaged snacks are sold. This is likely to have a positive impact on sales of NRT smoking cessation aids. Coupled with the economic recovery, which should coincide with other innovations, this should give a breath of fresh air to the category.

CATEGORY INDICATORS

  • Table 81 Number of Smokers by Gender 2005-2010

CATEGORY DATA

  • Table 82 Sales of NRT Smoking Cessation Aids by Category: Value 2005-2010
  • Table 83 Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2005-2010
  • Table 84 NRT Gum Flavours: % Value Breakdown 2006-2010
  • Table 85 NRT Smoking Cessation Aids Company Shares by Value 2006-2010
  • Table 86 NRT Smoking Cessation Aids Brand Shares by Value 2007-2010
  • Table 87 Forecast Sales of NRT Smoking Cessation Aids by Category: Value 2010-2015
  • Table 88 Forecast Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2010-2015

Sports Nutrition in Belgium - Category Analysis

HEADLINES

TRENDS

  • Despite the persisting effects of the economic crisis, attitudes towards sport nutrition products seemed to be increasingly favourable over 2009-2010. Demand was sustained by the recruitment of beginners, due to the popularisation of sport in Belgium, and the loyalty of sportsmen who already purchased such products. According to one player “Belgians prefer to sacrifice one or two restaurants, but more rarely sport, mainly now that they are aware of weight/obesity problems.” In addition, sport is an anti-stress remedy, which can be useful during a gloomy economic period.

COMPETITIVE LANDSCAPE

  • Sales in sport nutrition were still concentrated among the top three companies, which secured a 55% share of value sales in 2010. The remainder was much more fragmented than the top three, with many local, almost artisanal, players offering one or two products. With a 21% value share, the leader was QNT, which replaced Nature’s Best Belgium in 2010.

PROSPECTS

  • Marketers predict the development of alternative channels to sports centres and healthfood shops in coming years. Manufacturers are focusing on developing activities here, as prices and margins can be much more interesting than in store-based retailing. For instance, Internet retailing still has room for growth. In 2010, its share remained modest, probably due to the absence of large web stores in the country. Local manufacturers deemed web sites in France for instance as being more complete and particularly more aggressive in terms of promotion and discounts. In specialised sports outlets the Decathlon specialist chain should benefit from new openings in the country, and thus increasing traffic.

CATEGORY DATA

  • Summary 18 Sports Nutrition Category Rankings 2010
  • Table 89 Sales of Sports Nutrition: Value 2005-2010
  • Table 90 Sales of Sports Nutrition: % Value Growth 2005-2010
  • Table 91 Sports Nutrition By Format: % Value Breakdown 2007-2010
  • Table 92 Sports Nutrition Company Shares 2006-2010
  • Table 93 Sports Nutrition Brand Shares 2007-2010
  • Table 94 Forecast Sales of Sports Nutrition: Value 2010-2015
  • Table 95 Forecast Sales of Sports Nutrition: % Value Growth 2010-2015

Vitamins and Dietary Supplements in Belgium - Category Analysis

HEADLINES

TRENDS

  • Most industry sources agree that vitamins and dietary supplements experienced a slowdown in 2010. This slowdown was partly attributed to the weak recovery of the local economy and the subsequent impact on consumer purchasing power. Marketers also pointed to increasingly tough juridical constraints or medical surveys regarding product claims, even within the most promising niches. For instance, numerous surveys infirmed the claims of glucosamine and put pressure on the potential of such products in 2010.

VITAMINS

DIETARY SUPPLEMENTS

COMPETITIVE LANDSCAPE

  • Due to the presence of players from different backgrounds and countries and positioned in various distribution channels, the competitive environment of vitamins and dietary supplements was still highly fragmented in 2010. There were no clear leaders setting trends, despite the presence of many dynamic brands. The top six NBOs accounted for exactly one-third of value sales of vitamins and dietary supplements in 2010.

PROSPECTS

  • Most marketers find it difficult to have an outlook in vitamins and dietary supplements. First, some manufacturers have the feeling the most promising products of the categories, including probiotics and glucosamine, are enhanced with too-audacious claims. The growing number of brands in probiotics or combination formulas, or multivitamins with probiotics, may exhaust consumers’ interest.

CATEGORY DATA

  • Table 96 Summary1 Dietary Supplements: Brand Ranking by Positioning 2010
  • Table 97 Sales of Vitamins and Dietary Supplements by Category: Value 2005-2010
  • Table 98 Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2005-2010
  • Table 99 Dietary Supplements by Positioning 2005-2010
  • Table 100 Vitamins and Dietary Supplements Company Shares by Value 2006-2010
  • Table 101 Vitamins and Dietary Supplements Brand Shares by Value 2007-2010
  • Table 102 Vitamins Brand Shares by Value 2007-2010
  • Table 103 Dietary Supplements Brand Shares by Value 2007-2010
  • Table 104 Forecast Sales of Vitamins and Dietary Supplements by Category: Value 2010-2015
  • Table 105 Forecast Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2010-2015

Weight Management in Belgium - Category Analysis

HEADLINES

TRENDS

  • Sales of weight management products were strongly impacted by the launch of OTC obesity on 15 May with the entrance of Alli from GlaxoSmithKline. Entering the Belgian market, traditionally highly regulated, seemed impossible at first sight for the UK brand. Nonetheless, instead of starting by getting the local AMM (Authorisation to be Marketed), it identified in the EU its “ally” in order to lead a better targeted and efficient lobbying campaign. This paid off as GlaxoSmithKline managed to obtain European authorisation at the end of 2008, which notably opened the doors to the Belgian market in 2009.

COMPETITIVE LANDSCAPE

  • Herbalife Belgium was the leader of weight management with 24% of value sales in 2010. It was the outright leader in direct selling, the other co-leader of the distribution of weight management products. Traditional manufacturers and retailers often tended to underestimate the role of this channel, which enjoyed a strong peak of sales in 2009, notably due to the recruitment of more sales forces during the crisis in direct selling.

PROSPECTS

  • Sales of weight management products should be impacted by two converse trends over the forecast period. On one hand, Alli from GlaxoSmithKline is set to forge ahead and lend strong support to still fragile sales in weight management products. On the other hand the setting of new legislation regarding claims in functional food, dietary supplements, herbal/traditional products and slimming products should constrain the category’s potential. Given that claims and results in the latter are almost never backed/supported by scientific surveys, most miracle promises should be forbidden, and innovation in weight management could cross a rather sterile period in the short term. In addition, criticisms by nutritionists are expected to become tougher in the media. In the press the number of articles arguing that weight management products do not work and often result in users putting weight back on increased over 2009-2010, with this trend expected to continue into the forecast period.

CATEGORY DATA

  • Table 106 Sales of Weight Management: Value 2005-2010
  • Table 107 Sales of Weight Management: % Value Growth 2005-2010
  • Table 108 Weight Management Company Shares 2006-2010
  • Table 109 Weight Management Brand Shares 2007-2010
  • Table 110 Forecast Sales of Weight Management: Value 2010-2015
  • Table 111 Forecast Sales of Weight Management: % Value Growth 2010-2015

Wound Care in Belgium - Category Analysis

HEADLINES

TRENDS

  • Sales of wound care were marked by the decline of some added value products, more particularly liquid plasters and haemostatic sprays, which collapsed in sticking plasters/adhesive bandages. This high-tech niche slumped as its novelty effect wore off and its high unit prices, just as consumers became more selective and price sensitive in the consumer healthcare environment. In Belgium, such products took off in 2008 as a result of extensive advertising campaigns, but sales waned in 2009 and 2010 once TV advertising support came to an end.

COMPETITIVE LANDSCAPE

  • Beiersdorf was the absolute leader in wound care in 2010 with a 41% value share. A well-established presence in both of the main distribution channels, with Hansaplast dominant in grocery retailers and Hansaplast Med in pharmacies, enabled Beiersdorf to still lead the pack. Already a leader in basic plasters, Beiersdorf focused on sticking plasters for feet and blisters in order to increase its share against Compeed, the leader of this segment, and other brands such as Diable Vert, Scholl and Dermaplast. After a slight decline in 2010 due to the strong offensive by Compeed in pharmacies and the aggressiveness of private label and low-cost products in grocery retailers, it kept its value share intact in 2010.

PROSPECTS

  • The most profitable top end of the wound treatments category is likely to see a slowdown in the context of economic recession in the short term. The maturity of basic sticking plasters, the further penetration of private label products in the grocery channel and the on-going decline of “other wound treatments” should erode added value, unit prices and thus growth in the category over the forecast period.

CATEGORY DATA

  • Table 112 Sales of Wound Care by Category: Value 2005-2010
  • Table 113 Sales of Wound Care by Category: % Value Growth 2005-2010
  • Table 114 Wound Care Company Shares by Value 2006-2010
  • Table 115 Wound Care Brand Shares by Value 2007-2010
  • Table 116 Forecast Sales of Wound Care by Category: Value 2010-2015
  • Table 117 Forecast Sales of Wound Care by Category: % Value Growth 2010-2015

Segmentation

Segmentation

This market research report includes the following:

  • Consumer Health
    • OTC
      • Adult Mouth Care
      • Analgesics
        • Systemic Analgesics
          • Adult Analgesics
            • Acetaminophen
            • Aspirin
            • Combination Products - Analgesics
            • Diclofenac
            • Dipyrone
            • Ibuprofen
            • Ketoprofen
            • Naproxen
          • Child-Specific Analgesics
            • Child-Specific Acetaminophen
            • Child-Specific Aspirin
            • Child-Specific Combination Products - Analgesics
            • Child-Specific Diclofenac
            • Child-Specific Dipyrone
            • Child-Specific Ibuprofen
            • Child-Specific Ketoprofen
            • Child-Specific Naproxen
        • Topical Analgesics/Anaesthetic
      • Calming and Sleeping
      • Cough, Cold and Allergy (Hay Fever) Remedies
        • Antihistamines/Allergy Remedies (Systemic)
        • Child-Specific Cough, Cold and Allergy Remedies
          • Child-Specific Allergy Remedies
          • Child-Specific Cough/Cold Remedies
        • Combination Products - Cough, Cold and Allergy (Hay Fever) Remedies
        • Cough Remedies
        • Decongestants
          • Nasal Sprays
          • Oral Decongestants
          • Inhalant Decongestants
          • Decongestant Rubs
          • Nasal Decongestant Drops
          • Nasal Decongestant Plasters
        • Medicated Confectionery
        • Pharyngeal Preparations
      • Digestive Remedies
        • Child-Specific Digestive Remedies
          • Child-Specific Diarrhoeal Remedies
          • Child-Specific Indigestion and Heartburn Remedies
          • Child-Specific Laxatives
          • Child-Specific Motion Sickness Remedies
        • Diarrhoeal Remedies
        • IBS Treatments
        • Indigestion and Heartburn Remedies
          • Antacids
          • Antiflatulents
          • Digestive Enzymes
          • H2 Blockers
          • Proton Pump Inhibitors
        • Laxatives
        • Motion Sickness Remedies
      • Ear Care
      • Emergency Contraception
      • Eye Care
        • Allergy Eye Care
        • Standard Eye Care
      • Medicated Skin Care
        • Acne Treatments
        • Medicated Shampoos
        • Topical Antifungals
        • Vaginal Antifungals
        • Hair Loss Treatments
        • Nappy (Diaper) Rash Treatments
        • Antiparasitics/Lice (Head and Body) Treatments
        • Antipruritics
        • Child-Specific Medicated Skin Care
        • Cold Sore Treatments
        • Haemorrhoid Treatments
        • Topical Allergy Remedies/Antihistamines
        • Topical Germicidals/Antiseptics
      • NRT Smoking Cessation Aids
        • NRT Gum
        • NRT Inhalators
        • NRT Lozenges
        • NRT Patches
        • Other NRT
      • OTC Triptans
      • Wound Care
        • First Aid Kits
        • Sticking Plasters/Adhesive Bandages
        • Gauze, Tape and Other Wound Care
    • Sports Nutrition
    • Vitamins and Dietary Supplements
      • Child-Specific Vitamins and Dietary Supplements
      • Dietary Supplements
        • Combination Dietary Supplements
        • Herbal/Traditional Dietary Supplements
          • Combination Herbal/Traditional Dietary Supplements
          • Echinacea
          • Evening Primrose Oil
          • Garlic
          • Ginkgo Biloba
          • Ginseng
          • St John's Wort
          • Other Herbal/Traditional Dietary Supplements
            • Artichoke
            • Cranberry
            • Isoflavones
            • Spirulina
            • Other Other Herbal/Traditional Dietary Supplements
        • Non-Herbal Dietary Supplements
          • Calcium Supplements
          • Co-Enzyme Q10
          • Combination Non-Herbal Dietary Supplements
          • Eye Health Supplements
          • Fish Oils
            • Cod Liver Oil
            • Other Fish Oils
          • Glucosamine
          • Mineral Supplements
          • Omega-3-6-9 (Fish and Non-Fish)
          • Probiotic Supplements
          • Protein Powder
          • Royal Jelly
          • Sam-E
          • Other Non-Herbal Dietary Supplements
            • Lecithin
            • Other Other Non-Herbal Dietary Supplements
      • Tonics and Bottled Nutritive Drinks
      • Vitamins
        • Multivitamins
        • Single Vitamins
          • Vitamin A
          • Vitamin B
          • Vitamin C
          • Vitamin D
          • Vitamin E
          • Other Single Vitamins
    • Weight Management
      • Meal Replacement Slimming
      • OTC Obesity
      • Slimming Teas
      • Weight Loss Supplements
      • Other Slimming Products
    • Herbal/Traditional Products
      • Herbal/Traditional Analgesics
      • Herbal/Traditional Calming and Sleeping Products
      • Herbal/Traditional Cough, Cold and Allergy (Hay Fever) Remedies
      • Herbal/Traditional Digestive Remedies
      • Herbal/Traditional Medicated Skin Care
      • Herbal/Traditional Medicinal Teas
      • Herbal/Traditional Smoking Cessation Aids
      • Herbal/Traditional Child-Specific Dietary Supplements
      • Herbal/Traditional Dietary Supplements
      • Herbal/Traditional Tonics and Bottled Nutritive Drinks
    • Allergy Care
      • Allergy Eye Care
      • Antihistamines/Allergy Remedies (Systemic)
      • Child-Specific Allergy Remedies
      • Topical Allergy Remedies/Antihistamines
    • Child-Specific Consumer Health
      • Child-Specific Analgesics
        • Child-Specific Acetaminophen
        • Child-Specific Aspirin
        • Child-Specific Combination Products - Analgesics
        • Child-Specific Diclofenac
        • Child-Specific Dipyrone
        • Child-Specific Ibuprofen
        • Child-Specific Ketoprofen
        • Child-Specific Naproxen
      • Child-Specific Cough, Cold and Allergy Remedies
        • Child-Specific Allergy Remedies
        • Child-Specific Cough/Cold Remedies
      • Child-Specific Digestive Remedies
        • Child-Specific Diarrhoeal Remedies
        • Child-Specific Indigestion and Heartburn Remedies
        • Child-Specific Laxatives
        • Child-Specific Motion Sickness Remedies
      • Child-Specific Medicated Skin Care
      • Nappy (Diaper) Rash Treatments
      • Child-Specific Vitamins and Dietary Supplements

Statistics Included

Statistics Included

For each category and subcategory you will receive the following data in Excel format:

From Passport

  • Market sizes
  • Company shares
  • Brand shares
  • Distribution
  • Analysis by format
  • Analysis by positioning
  • Analysis by type
  • Herbal/traditional vs standard
  • Pricing

Market size details:

  • Retail volume
  • Retail volume % growth
  • Retail volume per capita
  • Retail value retail selling price % growth
  • Retail value retail selling price local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price real (constant 2008) prices % growth
  • Retail value retail selling price real (constant 2008) prices local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price real (constant 2008) prices per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price % growth
  • Retail value manufacturer selling price local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price real (constant 2008) prices % growth
  • Retail value manufacturer selling price real (constant 2008) prices local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price real (constant 2008) prices per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price nominal (current) prices % growth
  • Retail value retail selling price nominal (current) prices local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price nominal (current) prices per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price nominal (current) prices % growth
  • Retail value manufacturer selling price nominal (current) prices local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price nominal (current) prices per capita local currency, USD, EUR, GBP, CHF, JPY

Methodology

Methodology

Global insight and local knowledge

With 40 years’ experience of developed and emerging markets, Euromonitor International’s research method is built on a unique combination of specialist industry knowledge and in-country research expertise.

This approach is what enables us to achieve our goal of building a market consensus view of size, shape and trends across the full distribution universe of each category. We factor in whichever channels are relevant, from large-scale grocery to direct sellers, from discount stores to local mom-and-pop outlets.

Industry specialists

Each industry we cover is managed by an Industry Manager and team of Industry Analysts who research and report on their specialist categories all year round.

Our collaborative approach to research means that these industry teams are in constant dialogue with industry players and opinion formers. The planning of our research programmes reflects latest market trends and industry events. In completing each update project, this provides invaluable input to the testing, review and finalisation of our data.

The specialist in-house teams bring together findings from all stages of the annual research process. They work closely with in-country analysts, assess and challenge data and exercise final editorial control over the publication of new data and analysis.

Country and regional analysts

Our in-country analyst network is managed by country and regional analysts in our offices around the world. Working closely with each in-country team, the regional research management team ensures that all country researchers are well schooled in best practices, from the information collected in store checks, to the dialogue we build in trade surveys. Our country analysts ensure that national reports explain the data trends and provide clear insights into the local market’s dynamics.

In-country research network

To deliver fresh insights every year in countries all around the world, we believe the strongest approach is to use analysts on the ground. They bring fluency in local language, physical proximity to the best sources, an ability to engage directly with local industry contacts, and an awareness of how the products and services we study are advertised, sold and consumed. These are essential parts of our ability to report incisively on these markets.

Research Methodology

Our research methods

Each Euromonitor International industry report is based on a core set of research techniques:

Desk research

With industry events, corporate activity, trends and new product introductions tracked year round by our industry team, desk research provides a starting point for the in-country research programme. Our in-country researchers will access the following sources:

  • National statistics offices governmental and official sources
  • National and international trade press
  • National and international trade associations
  • Industry study groups and other semi-official sources
  • Company financials and annual reports
  • Broker reports
  • Online databases
  • The financial, business and mainstream press

Accessing sources is only the first step. The ability to interpret and reconcile often conflicting information across multiple sources is a key aspect of the added value we provide.

Store checks

Store checks are an integral part of our methods for product industries. Carried out on the ground across a relevant mix of channels, the information gained provides first-hand insights into the products we are researching, specifically:

  • Place: We track products in all relevant channels, selective and mass, store and non-store
  • Product: What are innovations in products, pack sizes and formats?
  • Price: What are brand price variations across channels, how do private label’s prices compare to those of branded goods?
  • Promotion: What are marketing and merchandising trends, offers, discounts and tie-ins?

Findings are cross-referenced with brand share data analysis. The results, combined with the findings of desk research, provide a strong basis for identifying key areas of questioning to take forward into our trade survey.

Trade survey

Interaction with global players at corporate HQ and regional levels is complemented by unique local data and insights from our in-country trade surveys around the world. Through the high profile of the Euromonitor International brand, we are able to talk directly to a wide range of sources and therefore inform our analysis with the knowledge and opinions of the leading operators in the market.

Trade surveys allow us to:

  • Fill gaps in available published data per company
  • Generate a consensus view of the size, structure and strategic direction of the category
  • Access year-in-progress data where published sources are out of date
  • Evaluate the experts’ views on current trends and market developments

In building our composite industry view, we engage with a variety of personnel in key players at all points of the supply chain: materials suppliers, manufacturers, distributors, retailers and service operators. We also interview desk research sources: industry associations; study groups; and third party observers from the trade and financial press.

Our objective is to engage in conversation with trade sources in which we exchange ideas and views on the industry, sharing our work-in-progress findings on supply/demand dynamics and potential. This dialogue enhances both parties’ understanding of the local market. The scope and reach of our trade survey also serves to eliminate bias (intentional and unintentional) from any single source.

Company analysis

At a global level, our company research combines our mix of industry interaction and use of secondary sources such as annual accounts, broker reports, financial press and databases. From a data perspective, the aim is to build “top-down” estimates of major players’ total global and regional sales.

At a country level, in line with local reporting requirements, we access annual accounts, national-specific company databases and local company websites. These are all invaluable sources as we build a view of each domestic player’s size and position within very specific categories of the industry.

Forecasts

Data projections and future performance analysis are key elements of Euromonitor International’s market intelligence. Working with historic trends of 15 years or more, a key aspect of our trade survey is to engage industry insider views of the next five years. Will volumes maintain their historic trend? Will price increases or falls of recent years continue, accelerate or slow down? Will increasing demand for one product cannibalise sales of another?

Forecasts represent many of the essential conclusions we have reached about the current state of the market, how it works and how it behaves under different macro and micro conditions. Our written analysis will state the assumptions and the trade opinion behind whether our predictions are optimistic or pessimistic, so that clients can use our statistical forecasts with confidence.

Data validation

All data is subjected to an exhaustive review process, at country, regional and global levels.

The interpretation and review of sources and data inputs forms a central part of the collaboration between industry teams and country researchers. Numbers are delivered to regional and global offices with an audit trail of sources and calculations to allow for a thorough evaluation of data sense and integrity.

Upon completion of the country review phase, data is then reviewed on a comparative basis at regional and then at a global level. Comparative checks are carried out on per capita consumption and spending levels, growth rates, patterns of category and subcategory breakdowns and distribution of sales by channel. Top-down estimates are reviewed against bottom-up regional and global market and company sales totals.

Where marked differences are seen between proximate country markets or ones at similar developmental levels, supplementary research is conducted in the relevant countries to confirm and/or amend those findings. This process ensures international comparability across the database, that consistent category and subcategory definitions have been used and that all data has been correctly tested. We make sure that possible discrepancies between different published sources have been reconciled and that our interpretation of opinion and expectation from each country’s trade sources has been applied to form a coherent international pattern.

Market analysis

Another integral part of all our research programmes is that all Euromonitor International data is accompanied by clear written analysis. From a research perspective, this explains and substantiates data findings. From a client perspective, this offers unique insights into local consumption trends, routes to market, brand preferences, channel dynamics and future trends.

Our country level analysis also provides invaluable input into the ability of our central industry specialist teams to marry local insights with strategic conclusions on the direction of the market regionally and globally.

my pages

Want to find out more about this report?

RELATED

Country Report

Consumer Lifestyle

Future Demographic

Country Report